| Code | CSB-RA015007MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ocrelizumab, targeting MS4A1 (CD20), a cell surface phosphoprotein exclusively expressed on B lymphocytes from pre-B to mature stages. CD20 plays a critical role in B-cell activation, proliferation, and differentiation by regulating calcium influx and cell cycle progression. This target is centrally implicated in autoimmune disorders and B-cell malignancies, as aberrant B-cell activity drives pathogenic immune responses in conditions such as multiple sclerosis, rheumatoid arthritis, and non-Hodgkin lymphoma.
Ocrelizumab is a humanized anti-CD20 monoclonal antibody approved for treating relapsing and primary progressive forms of multiple sclerosis. It functions by selectively depleting CD20-expressing B cells through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis, while preserving immune reconstitution capacity. This biosimilar antibody serves as a valuable research tool for investigating B-cell biology, autoimmune disease mechanisms, neuroinflammation pathways, and therapeutic antibody development studies.
There are currently no reviews for this product.